Cover Image
市場調查報告書

勝肽的癌症治療:全球市場及開發平台分析

Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014

出版商 PNS Pharma 商品編碼 311225
出版日期 內容資訊 英文 556 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
勝肽的癌症治療:全球市場及開發平台分析 Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014
出版日期: 2014年08月01日 內容資訊: 英文 556 Pages
簡介

抑制或根絕癌細胞產生的傳統方法,在癌症治療上一直成果有限。由於這些方法特異性低、缺乏安全性、副作用也多,研究者一直在摸索著更好的解決方案。其中由於勝肽不具有傳統方法之缺點,又是個有效且可行之治療方法,因而輩受注目。

本報告提供癌症治療勝肽的市場相關調查,提供您勝肽的癌症治療機制,勝肽癌症治療藥的臨床實驗平台(階段·適應症·企業·國別),彙整已上市產品的相關考察,市場規模的變化與預測,市場影響因素分析,主要企業簡介等資料。

第1章 勝肽的癌症治療:簡介

第2章 勝肽的癌症治療機制

第3章 勝肽的癌症治療市場:展望

  • 市場概要
  • 癌症勝肽的臨床實驗平台:概要

第4章 勝肽的癌症治療市場:動態

  • 有利的成長參數
  • 應該解決的主要課題

第5章 勝肽的癌症治療市場:未來的成長預測

第6章 勝肽的癌症治療藥的臨床實驗平台:階段·適應症·企業·國別

  • 調查
  • 前臨床
  • 臨床
  • 階段0
  • 階段I
  • 階段I/II
  • 階段II
  • 階段III

第7章 已上市勝肽癌症治療藥的考察:適應症·國家·各企業

第8章 中止·暫停中的勝肽癌症治療藥臨床試驗:階段·適應症·企業·各國

  • 沒有發展報告
  • 中止
  • 撤退
  • 延期

第9章 競爭環境

  • AngioChem
  • Antigen Express
  • Amgen
  • GlaxoSmithKline
  • Galena Biopharma
  • Ipsen
  • Merck & Co
  • PeptiDream
  • Roche
  • Sanofi
目錄

The conventional methods developed to prevent and eradicate the prevalence of cancer have achieved limited success in cancer treatment. These methods are confined to low specificity, safety and large number of side effects, which prompted the researchers to look for a better solution. It has been discovered that peptides can be used for effective and viable treatment of cancer without having disadvantages of conventional methods. The quintessential for using peptide cancer therapeutics is that they have high specificity, safety and efficacy which is not provide by therapeutics available in market.

The completion of human genome sequencing has helped in the research and development of peptide cancer therapeutics. The data allowed the researchers to look deep into the root cause of cancer hidden in human genome. This has allowed targeting cancer cells with high accuracy; thus, increasing the probability of treatment with high success rates. Using this data several novel molecules are being developed, which will have higher stability, effective delivery and minimal or no side-effects.

Peptide cancer therapeutics has edge in treating rare type of cancers. Conventional approaches of cancer treatments are unable to treat them successfully. Sometimes these approaches cannot be used due to unspecificity or they are not effective at all. For instance, brain cancer is a rare type of cancer that falls in this category. Brain is a very sensitive organ, to protect itself from unwanted substances it has developed blood brain barrier. It very difficult to breach, here conventional cancer therapeutics faces a sever challenge. On the other hand, peptide cancer therapeutics is able to overcome this barrier. Markets for these medicines have a huge potential and many medicines are under various phases of clinical trials

Peptide cancer therapies hold a promising future for the treatment of cancer. Various clinical trials studies have demonstrated the fact that the potential of peptide based drugs to prevent and eradicate cancer is far effective than conventional cancer therapy. In some studies, it has been found that combinatorial therapies will be more effective than individual methods. In combinatorial therapy, both conventional and peptide based cancer therapeutics are used for the treatment.

"Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014" Report Highlight:

  • Mechanism & Market Overview of Peptide Cancer Therapeutics
  • Clinical Pipeline by Analysis Phase, Indication, Company & Country
  • Peptide Cancer Drugs in Pipeline: 183 Drugs
  • Marketed Peptide Cancer Drugs: 20 Drugs
  • Majority Drugs in Preclinical Phase: 75 Drugs
  • Suspended & Discontinued Peptide Cancer Drugs: 143 Drugs
  • Peptide Cancer Therapeutics Market Future Growth Prospects

Table of Contents

1. Introduction to Peptide Cancer Therapeutics

2. Mechanism of Peptide Cancer Therapeutics

3. Peptide Cancer Therapeutics Market Outlook

  • 3.1 Market Overview
  • 3.2 Cancer Peptide Clinical Pipeline Overview

4. Peptide Cancer Therapeutics Market Dynamics

  • 4.1 Favorable Growth Parameters
  • 4.2 Key Issues to be Resolved

5. Peptide Cancer Therapeutics Market Future Growth Prospects

6. Peptide Cancer Drug Clinical Pipeline by Phase, Indication, Company & Country

  • 6.1 Research
  • 6.2 Preclinical
  • 6.3 Clinical
  • 6.4 Phase-0
  • 6.5 Phase-I
  • 6.6 Phase-I/II
  • 6.7 Phase-II
  • 6.8 Phase-III

7. Marketed Peptide Cancer Drug Insight by Indication, Country & Company

8. Suspended & Discontinued Peptide Cancer Drug in Clinical Trial by Phase, Indication, Company & Country

  • 8.1 No Development Reported
  • 8.2 Discontinued
  • 8.3 Market Withdrawal
  • 8.4 Suspended

9. Competitive Landscape

  • 9.1 AngioChem
  • 9.2 Antigen Express
  • 9.3 Amgen
  • 9.4 GlaxoSmithKline
  • 9.5 Galena Biopharma
  • 9.6 Ipsen
  • 9.7 Merck & Co
  • 9.8 PeptiDream
  • 9.9 Roche
  • 9.10 Sanofi
  • Figure 1-1: Use of Peptides in Various Ailments
  • Figure 2-1: Mode of Action of Peptide Cancer Therapeutics
  • Figure 2-2: Targeted Peptide Cancer Therapeutics Development
  • Figure 3-1: Global Peptide Market (US$ Billion), 2013-2018
  • Figure 3-2: Global Peptide Cancer Drug Pipeline by Phase (%), 2014
  • Figure 3-3: Global Peptide Cancer Drug Pipeline by Phase (Number), 2014
  • Figure 3-4: No Development Reported in Peptide Cancer Drug Pipeline by Phase (%), 2014
  • Figure 3-5: No Development Reported in Peptide Cancer Drug Pipeline by Phase (Number), 2014
  • Figure 3-6: Discontinued Peptide Cancer Drug Pipeline by Phase (%), 2014
  • Figure 3-7: Discontinued Peptide Cancer Drug Pipeline by Phase (Number), 2014
  • Figure 3-8: Suspended Peptide Cancer Drug Pipeline by Phase (%), 2014
  • Figure 3-9: Suspended Peptide Cancer Drug Pipeline by Phase (Number), 2014
Back to Top